Fasting Windows and Workouts Fail to Melt Liver Fat in Rigorous Trial

Time-restricted eating has become one of the most talked-about health trends of the decade, promising everything from rapid weight loss to a cleaner liver, all without counting a single calorie. Now one of the most rigorous tests of that promise has delivered a sobering verdict. In the TEMPUS randomized controlled trial, conducted in Granada, Spain, and published in Nature Communications, researchers found that eight-hour time-restricted eating, supervised exercise, and even the combination of both did not reduce liver fat more effectively than standard lifestyle advice in adults with obesity.

The study focused on intrahepatic fat fraction, a precise measure of fat accumulation inside the liver obtained through magnetic resonance imaging. Fatty liver disease, once considered a footnote of metabolic medicine, has quietly become one of the most common chronic liver conditions worldwide, closely entangled with obesity, type 2 diabetes, and cardiovascular risk. Because excess fat inside the liver fuels insulin resistance and inflammation, finding lifestyle strategies that genuinely shrink it has become a major goal of prevention research. Yet, as the TEMPUS investigators report, the fashionable tools many people swear by may not outperform the basics.

The trial enrolled 187 adults with obesity, half of them women, and randomized them into four groups. One group received usual care, defined in this study as education about the Mediterranean diet and physical activity, a conventional and evidence-based foundation for metabolic health. A second group practiced time-restricted eating, confining all food intake to an eight-hour daily window. A third group undertook supervised exercise sessions, ensuring that the physical activity was actually performed rather than merely recommended. The fourth group combined both interventions, testing whether the metabolic timing of meals and the energy demands of exercise could act synergistically on liver fat.

What makes TEMPUS stand out in a crowded field of intermittent-fasting studies is its methodological discipline. The primary outcome assessors and the statisticians analyzing the data were blinded to which participants had been assigned to which group, reducing the risk of biased measurement, even though the intervention personnel necessarily knew the allocations. Recruitment ran from May 2023 to April 2024, and the trial was completed on 5 September 2025. All randomized participants were included in the primary intention-to-treat analysis, the most conservative and clinically honest way to evaluate an intervention, because it reflects what happens in the real world when people struggle to adhere to demanding regimens.

After twelve weeks, the magnetic resonance imaging results told a strikingly flat story. Compared with usual care, the change in intrahepatic fat fraction was essentially indistinguishable across the intervention arms. Time-restricted eating produced a difference of minus 0.4 percentage points, with a confidence interval stretching from minus 2.0 to plus 1.2 and a p-value of 0.93, about as close to a null result as statistics allows. Supervised exercise fared little better at minus 0.8 percentage points, and the combined approach at minus 1.1 percentage points, neither reaching statistical significance. Critically, there were also no meaningful differences among the three intervention groups themselves, meaning that adding exercise to fasting, or fasting to exercise, offered no measurable edge over either strategy alone.

These numbers matter because they challenge a widespread intuition. Time-restricted eating is often promoted as a uniquely powerful metabolic intervention, with proponents arguing that aligning food intake with circadian rhythms gives the liver extended nightly fasting periods to mobilize and burn stored fat. Animal studies have supported this idea, and smaller human trials have reported encouraging signals. But TEMPUS, with its imaging-based gold-standard outcome measure, its blinded assessment, and its active comparator that itself reflects sound dietary guidance, suggests that the short-term hepatic advantage of the eight-hour window may be far smaller than the hype implies, or possibly nonexistent.

The result also carries an important message about the comparator. Usual care in TEMPUS was not a neglectful control arm; it consisted of education on the Mediterranean diet and physical activity, an approach with a long track record of cardiovascular benefit. When a trendy intervention fails to beat a well-implemented conventional one, the fair conclusion is not necessarily that the trendy intervention is useless, but that its incremental value over established advice is limited, at least over a twelve-week horizon in this population. For clinicians and patients weighing where to invest effort, that distinction is crucial.

There are, of course, boundaries to what TEMPUS can claim. The intervention lasted twelve weeks, a relatively short window in the trajectory of a chronic condition that develops over years, so longer trials might reveal effects that a quarter of a year cannot capture. The participants were adults with obesity in Granada, Spain, and responses could differ across populations, baseline liver fat levels, or dietary backgrounds. The trial was registered as NCT05897073 and was investigator-initiated, funded by public research agencies including Spanish national programs and European Union funds, with the funding sources having no role in the design, conduct, or analysis, an arrangement that strengthens confidence in the independence of the findings.

The trial’s design choices deserve emphasis for anyone trying to interpret the deluge of fasting research. Many earlier studies compared time-restricted eating against unrestricted eating without controlling calories, making it hard to tell whether benefits came from the eating window itself or from the spontaneous calorie reduction that often accompanies it. Others lacked objective imaging of liver fat, relying instead on surrogate markers such as liver enzymes, which are notoriously insensitive. By measuring intrahepatic fat fraction directly with MRI and by including a supervised exercise arm, TEMPUS addressed both weaknesses simultaneously, which is precisely why its null result carries such weight.

For the millions of people who have restructured their days around an eating window, the TEMPUS findings are not a mandate to abandon the practice, particularly if it suits their lifestyle and helps them maintain a healthy weight. But they are a reminder that in nutrition science, as in so many domains, the most convincing effects tend to belong to the least glamorous strategies: a Mediterranean-style diet, regular physical activity, and sustainable habits maintained over the long term. The liver, it seems, does not much care when you eat, so much as what and how much, and no amount of metabolic timing can substitute for the fundamentals.

Subject of Research: Effects of time-restricted eating and supervised exercise on intrahepatic fat in adults with obesity

Article Title: Effects of time-restricted eating and supervised exercise on intrahepatic fat and cardiometabolic health in adults with obesity: the TEMPUS randomized controlled trial

Article References: Effects of time-restricted eating and supervised exercise on intrahepatic fat and cardiometabolic health in adults with obesity: the TEMPUS randomized controlled trial. (n.d.). https://doi.org/10.1038/s41467-026-78625-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78625-3

Keywords: time-restricted eating, intermittent fasting, intrahepatic fat, obesity, exercise, randomized controlled trial, fatty liver disease, Mediterranean diet, cardiometabolic health, MRI, TEMPUS trial, Nature Communications